細胞治療技術市場：製品（培地、血清、試薬、細胞培養容器、シングルユース機器、システム、ソフトウェア）、プロセス（細胞加工）、細胞タイプ（T細胞、幹細胞）、エンドユーザー（バイオファーマ、CMO）、地域別 - 2027年までの世界市場予測

Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single Use Equipment, Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Biopharma, CMOs), Region - Global Forecast to 2027

細胞治療技術市場は、2022年の40億米ドルから2027年には80億米ドルに達すると予測され、予測期間中のCAGRは14.6%となります。この成長の背景には、官民のパートナーシップの増加があります。複数の政府機関や民間... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年8月3日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	210	250	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

細胞治療技術市場は、2022年の40億米ドルから2027年には80億米ドルに達すると予測され、予測期間中のCAGRは14.6%となります。この成長の背景には、官民のパートナーシップの増加があります。複数の政府機関や民間企業が細胞治療の研究開発を強化するために多額の投資を行っており、それが細胞治療技術の需要急増につながり、市場成長を後押ししています。
"2021年、細胞の保存と流通、ハンドリングプロセス部門が市場の第2位のシェアを占める"
細胞の保存と分配は、細胞のスケールアッププロセスにおいて不可欠で重要なステップである。また、細胞を用いた医療製品や治療法の需要の増加に伴い、有限の細胞株や過剰に製造された細胞を保存するための信頼性の高い保存装置の需要が高まると予想されます。このような要因が、本市場セグメントの成長を牽引するものと考えられます。
"2021年の細胞治療技術市場では、CROとCMOが第2位のシェアを占めています。"
大きな需要に対応するため、製薬会社は臨床スケジュールの迅速化、事業継続性の維持、プロジェクトのためのリソースの確保を必要としています。このため、CROやCMOへの分析試験のアウトソーシングが増加し、同分野の市場成長を後押ししています。
Thermo Fisher Scientific, Inc.（米国）、Merck KGaA（ドイツ）、Danaher Corporation（米国）、Lonza Group（スイス）、Sartorius AG（ドイツ）、Terumo BCT（米国）、Becton, Dickinson and Company（米国）、Fresenius SE & Co.KGaA（ドイツ）、Avantor, Inc.（米国）、Bio-Techne Corporation（米国）、Corning Incorporated（米国）、FUJIFILM Irvine Scientific（米国）、MaxCyte Inc（米国）、Werum IT Solutions GmbH（ドイツ）、RoosterBio Inc（米国）、SIRION Biotech GmbH（ドイツ）、TrakCel（イギリス）、L7 Informatics, Inc.(米国）、Miltenyi Biotec GmbH（ドイツ）、STEMCELL Technologies（カナダ）、GPI Iberia（スペイン）、MAK-SYSTEM（米国）、OrganaBio, LLC（米国）、IxCells Biotechnology（中国）、Wilson Wolf Manufacturing Corporation（米国）など、主要企業が市場に進出しています。

"アジア太平洋地域細胞治療技術市場で最も成長率の高い地域"
アジア太平洋地域は、予測期間中に最も高いCAGRを記録すると予想されています。アジア太平洋地域の市場成長の主な要因としては、低コストでの製造の優位性、一人当たりの所得の増加、がん抑制ニーズの高まりなどが挙げられます。また、高齢者人口の増加も、同地域の細胞治療技術市場を活性化させています。
本レポートのために実施した主なインタビューは、以下のように分類されます。

- 回答者別供給側：80％、需要側：20
- 役職別マネージャー - 45%、CXOとディレクターレベル - 30%、エグゼクティブ - 25
- 地域別北米：20％、欧州：10％、アジア太平洋：55％、RoW：15
レポート掲載企業一覧
- サーモフィッシャーサイエンティフィック社（米国）
- Merck KGaA (ドイツ)
- ダナハーコーポレーション（米国）
- ロンザグループ（スイス）
- ザルトリウスAG（ドイツ）
- テルモBCT（米国）
- ベクトン・ディッキンソンアンドカンパニー（米国）
- フレゼニウス SE & Co.KGaA（ドイツ）
- Avantor, Inc.（米国）
- バイオテクネ・コーポレーション（米国）
- コーニング・インコーポレイテッド（米国）
- 富士フイルムアーバインサイエンティフィック（米国）
- マックスサイト社 (米国)
- Werum IT Solutions GmbH（ドイツ）
- ルースター・バイオ社（米国）
- SIRION Biotech GmbH（ドイツ）
- TrakCel（英国）
- L7 Informatics, Inc.（米国）
- Miltenyi Biotec GmbH (ドイツ)
- STEMCELL Technologies（カナダ）
- GPI Iberia（スペイン）
- MAK-SYSTEM (米国), OrganaBio, LLC (米国)
- IxCells Biotechnology（中国）
- ウィルソン・ウルフ・マニュファクチャリング・コーポレーション（米国）
調査対象
本レポートは、細胞治療技術市場の詳細なイメージを提供します。製品、プロセス、細胞タイプ、エンドユーザー、地域などの異なるセグメントにおける市場規模と将来の成長性を推定することを目的としています。また、主要な市場プレイヤーの企業プロファイルや最近の開発状況、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、細胞治療技術市場全体とそのサブセグメントにおける収益数の最も近い概算を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競争環境をより良く理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、利害関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、課題、トレンド、機会に関する情報を提供することを可能にします。

ページTOPに戻る

1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS AND EXCLUSIONS 32
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
FIGURE 1 CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION 32
1.3.2 YEARS CONSIDERED 33
1.4 CURRENCY CONSIDERED 33
1.5 LIMITATIONS 33
1.6 STAKEHOLDERS 34
1.7 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 2 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 36
2.1.2 PRIMARY DATA 36
FIGURE 3 BREAKDOWN OF PRIMARIES BY RESPONDENT, DESIGNATION, AND REGION: CELL THERAPY TECHNOLOGIES MARKET 37
2.2 MARKET ESTIMATION METHODOLOGY 38
FIGURE 4 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021 38
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021 38
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 39
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 39
2.3 MARKET GROWTH RATE PROJECTIONS 40
FIGURE 7 CELL THERAPY TECHNOLOGIES MARKET (SUPPLY SIDE): CAGR PROJECTIONS 41
FIGURE 8 CELL THERAPY TECHNOLOGIES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS 42
2.4 DATA TRIANGULATION 43
FIGURE 9 DATA TRIANGULATION METHODOLOGY 43
2.5 RESEARCH ASSUMPTIONS 44
2.6 RISK ANALYSIS 44
3 EXECUTIVE SUMMARY 45
FIGURE 10 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 45
FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022 VS. 2027 (USD MILLION) 46
FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022 VS. 2027 (USD MILLION) 46
FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 47
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF CELL THERAPY TECHNOLOGIES MARKET 48
4 PREMIUM INSIGHTS 49
4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW 49
FIGURE 15 INCREASING GOVERNMENT INVESTMENTS IN CELL-BASED RESEARCH TO DRIVE MARKET GROWTH 49
4.2 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SHARE, BY CELL TYPE AND COUNTRY (2021) 50
FIGURE 16 T CELLS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021 50
4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2022 VS. 2027 50
FIGURE 17 MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2027 50
4.4 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PROCESS, 2022 51
FIGURE 18 CELL PROCESSING SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022 51
4.5 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51
FIGURE 19 ASIA PACIFIC COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
FIGURE 20 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
5.2.1 DRIVERS 53
5.2.1.1 Increasing government investments in cell-based research 53
TABLE 1 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2019 (USD MILLION) 53
5.2.1.2 Rising incidence of chronic and infectious diseases 54
5.2.1.3 Large number of oncology-related cell therapy clinical trials 54
FIGURE 21 CANCER CELL THERAPY PIPELINE (MARCH 2019–MARCH 2020) 55
5.2.1.4 Increasing GMP certifications for cell therapy production facilities 55
TABLE 2 EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP 55
5.2.2 RESTRAINTS 56
5.2.2.1 High cost of cell-based research and low success rate 56
TABLE 3 COST OF CELL THERAPY EQUIPMENT 56
5.2.2.2 Dearth of skilled professionals 56
5.2.3 OPPORTUNITIES 57
5.2.3.1 Emergence of iPSCs as alternatives to ESCs 57
5.2.3.2 Increased focus on personalized medicine 57
5.2.3.3 Increasing public-private partnerships for development of cell therapies 58
5.2.3.4 Emerging Asian markets 58
5.2.4 CHALLENGES 58
5.2.4.1 Survival of small players and new entrants 58
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 59
FIGURE 22 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS 59
5.4 INDICATIVE PRICING MODEL ANALYSIS 59
TABLE 4 PRICING ANALYSIS OF CELL THERAPY PRODUCTS 59
5.5 TECHNOLOGY ANALYSIS 60
5.6 VALUE CHAIN ANALYSIS 60
FIGURE 23 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE 60
5.7 SUPPLY CHAIN ANALYSIS 61
FIGURE 24 CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS 62
5.8 ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET 62
FIGURE 25 ECOSYSTEM ANALYSIS 62
TABLE 5 SUPPLY CHAIN ECOSYSTEM 63
5.9 KEY CONFERENCES AND EVENTS IN 2022–2023 64
TABLE 6 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 64
5.10 REGULATORY ANALYSIS 65
5.10.1 NORTH AMERICA 65
TABLE 7 NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES 65
5.10.2 EUROPE 66
TABLE 8 EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES 66
5.10.3 ASIA PACIFIC 67
TABLE 9 ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES 67
5.10.4 REST OF THE WORLD 68
TABLE 10 REST OF THE WORLD: REGULATORY LANDSCAPE FOR CELL THERAPIES 68
5.11 PORTER’S FIVE FORCES ANALYSIS 69
TABLE 11 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 69
5.11.1 THREAT OF NEW ENTRANTS 69
5.11.2 THREAT OF SUBSTITUTES 69
5.11.3 BARGAINING POWER OF SUPPLIERS 69
5.11.4 BARGAINING POWER OF BUYERS 69
5.11.5 DEGREE OF COMPETITION 69
5.12 PATENT ANALYSIS 70
FIGURE 26 PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JANUARY 2012–JULY 2022 70
TABLE 12 INDICATIVE LIST OF PATENTS IN CELL THERAPY TECHNOLOGIES MARKET 70
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 71
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 71
FIGURE 27 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF CELL THERAPY PRODUCTS 71
5.13.2 BUYING CRITERIA FOR CELL THERAPY PRODUCTS 72
FIGURE 28 KEY BUYING CRITERIA FOR END USERS 72
6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT 73
6.1 INTRODUCTION 74
TABLE 13 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 74
6.2 MEDIA, SERA, AND REAGENTS 74
6.2.1 MEDIA, SERA, AND REAGENTS ARE INTEGRAL PARTS OF CELL PROCESSING 74
TABLE 14 CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY REGION, 2020–2027 (USD MILLION) 75
TABLE 15 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 16 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 17 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 76
6.3 CELL ENGINEERING PRODUCTS 76
6.3.1 AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS SUPPORTS MARKET GROWTH 76
TABLE 18 CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 76
TABLE 19 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 20 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 21 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 77
6.4 CELL CULTURE VESSELS 78
6.4.1 CELL CULTURE VESSELS ARE WIDELY USED FOR CELL GROWTH 78
TABLE 22 CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 23 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 24 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 25 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020–2027 (USD MILLION) 79
6.5 EQUIPMENT 79
TABLE 26 CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY REGION, 2020–2027 (USD MILLION) 80
TABLE 27 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 28 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 29 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 30 CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY TYPE, 2020–2027 (USD MILLION) 81
6.5.1 CELL PROCESSING EQUIPMENT 81
6.5.1.1 Cell processing equipment segment dominates cell therapy equipment market 81
TABLE 31 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY REGION, 2020–2027 (USD MILLION) 82
TABLE 32 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 33 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 34 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 83
6.5.2 SINGLE-USE EQUIPMENT 83
6.5.2.1 Benefits of single-use equipment have ensured end-user demand 83
TABLE 35 CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 36 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 37 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 38 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 84
6.5.3 OTHER EQUIPMENT 85
TABLE 39 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 40 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 41 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 42 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 86
6.6 SYSTEMS AND SOFTWARE 86
6.6.1 SYSTEMS AND SOFTWARE ARE USED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING 86
TABLE 43 CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY REGION, 2020–2027 (USD MILLION) 87
TABLE 44 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 45 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 46 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 88

6.7 OTHER PRODUCTS 88
TABLE 47 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 88
TABLE 48 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 49 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 50 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 89
7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS 90
7.1 INTRODUCTION 91
TABLE 51 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 91
7.2 CELL PROCESSING 91
7.2.1 CELL PROCESSING MAKES WIDE USE OF CELL THERAPY INSTRUMENTS 91
TABLE 52 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2020–2027 (USD MILLION) 91
TABLE 53 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 54 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 55 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.3 CELL PRESERVATION, DISTRIBUTION, AND HANDLING 93
7.3.1 INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH 93
TABLE 56 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2020–2027 (USD MILLION) 93
TABLE 57 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 58 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 59 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.4 PROCESS MONITORING AND QUALITY CONTROL 95
7.4.1 PROCESS MONITORING IS ESSENTIAL TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING 95
TABLE 60 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 61 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 62 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 63 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020–2027 (USD MILLION) 96
8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE 97
8.1 INTRODUCTION 98
TABLE 64 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 98
8.2 T CELLS 98
8.2.1 RESEARCH CONDUCTED ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH 98
TABLE 65 CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2020–2027 (USD MILLION) 99
TABLE 66 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 67 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 68 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020–2027 (USD MILLION) 100
8.3 STEM CELLS 100
8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE SEGMENT GROWTH 100
TABLE 69 CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2020–2027 (USD MILLION) 101
TABLE 70 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 71 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 72 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 OTHER CELLS 102
TABLE 73 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2020–2027 (USD MILLION) 102
TABLE 74 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 75 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 76 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 CELL THERAPY TECHNOLOGIES MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 77 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 105
9.2 BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 105
9.2.1 RISING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE SEGMENT GROWTH 105
TABLE 78 CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 106
TABLE 79 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 80 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 81 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 107
9.3 CROS AND CMOS 107
9.3.1 RISING FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH 107
TABLE 82 CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY REGION, 2020–2027 (USD MILLION) 107
TABLE 83 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 84 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 85 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020–2027 (USD MILLION) 108
9.4 RESEARCH INSTITUTES AND CELL BANKS 109
9.4.1 MARKET GROWTH IS SUPPORTED BY RISING RESEARCH ACTIVITY 109
TABLE 86 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY REGION, 2020–2027 (USD MILLION) 109
TABLE 87 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 88 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020–2027 (USD MILLION) 110
TABLE 89 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020–2027 (USD MILLION) 110
10 CELL THERAPY TECHNOLOGIES MARKET, BY REGION 111
10.1 INTRODUCTION 112
TABLE 90 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2020–2027 (USD MILLION) 112
10.2 NORTH AMERICA 112
FIGURE 29 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 113
TABLE 91 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 113
TABLE 92 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 114
TABLE 93 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 94 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 114
TABLE 95 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 115
TABLE 96 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D activities to support market growth 115
TABLE 97 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 116
TABLE 98 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 99 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 116
TABLE 100 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 117
TABLE 101 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 117
10.2.2 CANADA 117
10.2.2.1 Increasing government funding to drive adoption of cell therapy instruments 117
TABLE 102 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 118
TABLE 103 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 104 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 118
TABLE 105 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 119
TABLE 106 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 119
10.3 EUROPE 119
TABLE 107 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 108 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 120
TABLE 109 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 110 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 121
TABLE 111 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 121
TABLE 112 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 121
10.3.1 GERMANY 122
10.3.1.1 Germany holds largest share of European market 122
TABLE 113 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 122
TABLE 114 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 115 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 123
TABLE 116 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 123
TABLE 117 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 123
10.3.2 UK 124
10.3.2.1 Favorable funding and investment scenario to drive market growth 124
TABLE 118 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 124
TABLE 119 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 120 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 125
TABLE 121 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 125
TABLE 122 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 125
10.3.3 FRANCE 126
10.3.3.1 Availability of government and private support to drive market growth 126
TABLE 123 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 126
TABLE 124 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 125 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 127
TABLE 126 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 127
TABLE 127 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 128
10.3.4 ITALY 128
10.3.4.1 Initiatives favoring cell and gene therapy development to support market growth 128
TABLE 128 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 129
TABLE 129 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 130 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 129
TABLE 131 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 130
TABLE 132 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 130
10.3.5 SPAIN 130
10.3.5.1 Increasing funding from private and public organizations to aid market growth 130
TABLE 133 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 131
TABLE 134 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 135 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 131
TABLE 136 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 132
TABLE 137 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 132
10.3.6 REST OF EUROPE 132
TABLE 138 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 133
TABLE 139 ROE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 133
TABLE 140 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 133
TABLE 141 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 134
TABLE 142 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 134
10.4 ASIA PACIFIC 134
FIGURE 30 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 135
TABLE 143 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 144 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 136
TABLE 145 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 146 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 136
TABLE 147 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 137
TABLE 148 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 137
10.4.1 CHINA 137
10.4.1.1 Increasing cell therapy-based trials to support market growth 137
TABLE 149 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 138
TABLE 150 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 138
TABLE 151 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 138
TABLE 152 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 139
TABLE 153 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 139
10.4.2 JAPAN 139
10.4.2.1 Rising geriatric population and growing disease prevalence to drive market growth 139
TABLE 154 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 140
TABLE 155 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 140
TABLE 156 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 157 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 141
TABLE 158 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 141
TABLE 159 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 141
10.4.3 INDIA 142
10.4.3.1 Favorable government regulations to support market growth 142
TABLE 160 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 142
TABLE 161 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 162 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 143
TABLE 163 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 143
TABLE 164 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 143
10.4.4 REST OF ASIA PACIFIC 144
TABLE 165 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 144
TABLE 166 ROAPAC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 144
TABLE 167 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 145
TABLE 168 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 145
TABLE 169 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 145
10.5 LATIN AMERICA 146
10.5.1 AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET GROWTH 146
TABLE 170 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 146
TABLE 171 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 172 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 147
TABLE 173 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 147
TABLE 174 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 147
10.6 MIDDLE EAST AND AFRICA 148
10.6.1 INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET GROWTH 148
TABLE 175 MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 148
TABLE 176 MIDDLE EAST AND AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 148
TABLE 177 MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION) 149
TABLE 178 MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 149
TABLE 179 MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 149
11 COMPETITIVE LANDSCAPE 150
11.1 INTRODUCTION 150
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 150
FIGURE 31 CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED 151
11.3 MARKET SHARE ANALYSIS 152
FIGURE 32 CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021) 152
TABLE 180 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION 152
11.4 REVENUE ANALYSIS 153
FIGURE 33 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021) 153
11.5 COMPANY EVALUATION MATRIX 154
FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX, 2021 154
11.5.1 STARS 155
11.5.2 EMERGING LEADERS 155
11.5.3 PERVASIVE PLAYERS 155
11.5.4 PARTICIPANTS 155
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES 156
FIGURE 35 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021 156
11.6.1 PROGRESSIVE COMPANIES 157
11.6.2 STARTING BLOCKS 157
11.6.3 RESPONSIVE COMPANIES 157
11.6.4 DYNAMIC COMPANIES 157
11.6.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 157
TABLE 181 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UPS/SMES 157
TABLE 182 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES 159
11.7 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 159
11.7.1 COMPANY FOOTPRINT (25 COMPANIES) 159
TABLE 183 COMPANY FOOTPRINT ANALYSIS: KEY PLAYERS 159
11.7.2 PRODUCT FOOTPRINT (25 COMPANIES) 160
TABLE 184 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS 160
11.7.3 PROCESS FOOTPRINT (25 COMPANIES) 161
TABLE 185 PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS 161
11.7.4 REGIONAL FOOTPRINT (25 COMPANIES) 162
TABLE 186 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS 162
11.8 COMPETITIVE SCENARIO AND TRENDS 163
11.8.1 PRODUCT LAUNCHES 163
TABLE 187 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES (JANUARY 2019–JULY 2022) 163
11.8.2 DEALS 164
TABLE 188 CELL THERAPY TECHNOLOGIES MARKET: DEALS (JANUARY 2019–JULY 2022) 164
11.8.3 OTHER DEVELOPMENTS 164
TABLE 189 CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS (JANUARY 2019–JULY 2022) 164
12 COMPANY PROFILES 165
12.1 KEY PLAYERS 165
(Business Overview, Products Offered, Recent Developments, MnM view, Key strengths/right to win, Strategic choices made, Weaknesses and competitive threats)*
12.1.1 THERMO FISHER SCIENTIFIC, INC. 165
TABLE 190 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 165
FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT 166
12.1.2 MERCK KGAA 170
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 170
FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT 171
12.1.3 DANAHER CORPORATION 174
TABLE 192 DANAHER CORPORATION: BUSINESS OVERVIEW 174
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT 175
12.1.4 LONZA GROUP 179
TABLE 193 LONZA GROUP: BUSINESS OVERVIEW 179
FIGURE 39 LONZA GROUP: COMPANY SNAPSHOT 180
12.1.5 SARTORIUS AG 182
TABLE 194 SARTORIUS AG: BUSINESS OVERVIEW 182
FIGURE 40 SARTORIUS AG: COMPANY SNAPSHOT 183
12.1.6 TERUMO BCT, INC. 185
TABLE 195 TERUMO CORPORATION: BUSINESS OVERVIEW 185
FIGURE 41 TERUMO CORPORATION: COMPANY SNAPSHOT 185
12.1.7 BECTON, DICKINSON AND COMPANY 187
TABLE 196 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 187
FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 188
12.1.8 FRESENIUS SE & CO. KGAA 189
TABLE 197 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW 189
FIGURE 43 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT 189
12.1.9 AVANTOR, INC. 191
TABLE 198 AVANTOR, INC.: BUSINESS OVERVIEW 191
FIGURE 44 AVANTOR, INC.: COMPANY SNAPSHOT 192
12.1.10 BIO-TECHNE CORPORATION 194
TABLE 199 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 194
FIGURE 45 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT 195
12.1.11 CORNING INCORPORATED 198
TABLE 200 CORNING INCORPORATED: BUSINESS OVERVIEW 198
FIGURE 46 CORNING INCORPORATED: COMPANY SNAPSHOT 199
12.1.12 FUJIFILM IRVINE SCIENTIFIC 200
TABLE 201 FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW 200
FIGURE 47 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT 201
12.1.13 MAXCYTE, INC. 202
TABLE 202 MAXCYTE: BUSINESS OVERVIEW 202
FIGURE 48 MAXCYTE: COMPANY SNAPSHOT 202
*Details on Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 204
12.2.1 WERUM IT SOLUTIONS 204
12.2.2 ROOSTERBIO, INC. 204
12.2.3 SIRION BIOTECH GMBH 205
12.2.4 TRAKCEL 205
12.2.5 L7 INFORMATICS 206
12.2.6 MILTENYI BIOTEC 206
12.2.7 STEMCELL TECHNOLOGIES INC. 207
12.2.8 GPI IBERIA (FORMERLY HEMASOFT) 209
12.2.9 MAK-SYSTEM 209
12.2.10 ORGANABIO, LLC 210
12.2.11 IXCELLS BIOTECHNOLOGIES 210
12.2.12 WILSON WOLF MANUFACTURING CORPORATION 211
13 APPENDIX 212
13.1 DISCUSSION GUIDE 212
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 215
13.3 CUSTOMIZATION OPTIONS 217
13.4 RELATED REPORTS 217
13.5 AUTHOR DETAILS 218

ページTOPに戻る

Table of Contents

Summary

The cell therapy technologies market is projected to reach USD 8.0 Billion by 2027 from USD 4.0 Billion in 2022, at a CAGR of 14.6% during the forecast period. The growth can be attributed to the increasing public-private partnerships. Several government and private organizations have made significant investments to strengthen R&D in cell therapy leading to surge in cell therapy technologies demand, hence propelling market growth.
“The cell preservation and distribution and handling process segment accounted for the second largest share of the market in 2021”
Cell preservation and distribution is an essential and vital step in the cell scaling-up process. In addition, with the growth in the demand for cell-based medical products and therapies, the demand for reliable storage equipment to preserve finite cell lines and cells manufactured in excess is expected to increase. This factor is expected to drive the growth of this market segment.
“The CROs and CMOs accounted for the second largest share of the cell therapy technologies market in 2021”
To cater the large demand, pharmaceutical companies need to speed up clinical timelines, maintain business continuity, and free up resources for projects. This has increased outsourcing analytical tests to CROs and CMOs, thereby boosting the segment market growth.
Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson and Company (US), Fresenius SE & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), GPI Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Manufacturing Corporation (US), are some of the major players operating in the market.

“Asia Pacific: The fastest-growing region in the cell therapy technologies market”
The Asia Pacific market is expected to register the highest CAGR during the forecast period. Some of the major factors contributing to the growth of the Asia Pacific market are low-cost manufacturing advantage, increasing per capita income, and growing need to curb cancer. In addition, the growth of geriatric population is also fueling the cell therapy technologies market in the region.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side - 20%
• By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• Danaher Corporation (US)
• Lonza Group (Switzerland)
• Sartorius AG (Germany)
• Terumo BCT (US)
• Becton, Dickinson and Company (US)
• Fresenius SE & Co. KGaA (Germany)
• Avantor, Inc. (US)
• Bio-Techne Corporation (US)
• Corning Incorporated (US)
• FUJIFILM Irvine Scientific (US)
• MaxCyte Inc. (US)
• Werum IT Solutions GmbH (Germany)
• RoosterBio Inc. (US)
• SIRION Biotech GmbH (Germany)
• TrakCel (UK)
• L7 Informatics, Inc. (US)
• Miltenyi Biotec GmbH (Germany)
• STEMCELL Technologies (Canada)
• GPI Iberia (Spain)
• MAK-SYSTEM (US), OrganaBio, LLC (US)
• IxCells Biotechnology (China)
• Wilson Wolf Manufacturing Corporation (US)
Research Coverage:
This report provides a detailed picture of the cell therapy technologies market. It aims at estimating the size and future growth potential of the market across different segments such as the product, process, cell type, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（三次医療）の最新刊レポート

MarketsandMarkets社の三次医療分野での最新刊レポート

本レポートと同じKEY WORD（end user）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（三次医療）の最新刊レポート

MarketsandMarkets社の三次医療分野での最新刊レポート

本レポートと同じKEY WORD（end user）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?